Professionals 227 Users Online

Chemotherapy Drugs Market

Market Study on Chemotherapy Drugs: Focus on Combination Therapy with Novel Drug Formulations to Increase

Chemotherapy Drugs Market Segmented By Drug Class (Alkylating Agents, Antimetabolites, Anti-tumour Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Plant Alkaloids)

Chemotherapy Drugs Market Outlook (2022-2032)

Worldwide revenue from the chemotherapy drugs market is estimated to reach US$ 157.7 Bn in 2022, with the global market forecasted to surge ahead at a CAGR of 7.7% to reach a valuation of US$ 331.3 Bn by the end of 2032.

The global market for chemotherapy drugs recorded a historic CAGR of 6.4% in the last 9 years from 2012 to 2021. Overall, chemotherapy drug sales accounted for 87.6% of the global oncology cancer drugs market in 2021.

Chemotherapy drugs include alkylating agents, antimetabolites, anti-tumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, plant alkaloids, corticosteroids, miscellaneous antineoplastic, and others.

The present focus is on improving drug formulation and innovating drugs of novel nature, which, if combined with another drug or molecule, increases the efficiency of the overall therapy or provides better results with reduced side effects. This gave rise to targeted therapy, immunotherapy, and others, which are part of the anti-cancer drugs market. Manufacturers with strong research and development teams stay ahead and help in the overall market growth.

Furthermore, governments are also increasing cancer medicine spending.

  • In 2020, the American Medical Association mentioned that U.S. spending has risen from US$ 50 Bn in 2017 to $75 Bn in 2021. Greater access to healthcare in pharmerging and lower-income nations in the rest of the globe increased spending, with total spending in these countries reaching US$ 25 billion in 2021, constituting 14% of global spending, rising from 11% in 2017.
  • After the pandemic, the International Agency for Research on Cancer, part of the World Health Organization, in 2021, estimated the number of patients gradually grew, and oncologists have reported a rise in the number of patients, ranging from a 1% increase in non-small cell lung cancer to a 20% increase in cervical cancer.

Because of population aging and easy access to care, cancer treatment levels in developed economies hold constant. As a result, the global number of patients treated is expanding at an exponential rate, creating opportunities for the chemotherapy drugs industry.

Chemotherapy Drugs Market Size (2022)

US$ 157.7 Bn

Projected Market Value (2032)

US$ 331.3 Bn

Global Market Growth Rate (2022-2032)

7.7% CAGR

Market Share of Top 5 Countries


Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Why is the Global Chemotherapy Drugs Market Growing?

“Increasing Product Launches and Regulatory Approvals

Regulations are critical in the pharmaceutical sector. Recently, regulatory agencies such as the United States Food and Drug Administration, the Therapeutic Goods Administration, and others have been proactive. There have been multiple launches, and the FDA has approved many drugs with novel characteristics and combinations.

For example,

  • Trilaciclib drug was introduced in 2021 for bone marrow suppression, which is the first of its kind to minimize the incidence of chemotherapy-influenced bone marrow suppression amongst persons receiving specific types of chemotherapy treating advanced-stage small cell lung cancer.
  • The FDA authorized tremelimumab, durvalumab, and platinum-based treatment in November 2022 for metastatic non-small cell lung cancer.

The introduction of these new drugs with regulatory approvals is expected to result in high treatment adoption rates, which, in turn, will drive market growth during the forecast period.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

Can Demand for Chemotherapy Drugs Be Affected in Any Way?

Alternatives and Improved Treatment Options

Over the last decade, scientific discoveries have accelerated, leading to the development of a variety of increasingly specialized medicines that can target malignancies at the molecular level. This is altering doctors' perspectives on cancer and ushering in a new era of cancer treatment.

Despite substantial advancements in these basic medicines, which include surgery, radiotherapy, and chemotherapy, their devastating side effect profiles have kept the search for novel cancer treatments alive.

Nausea and vomiting, exhaustion, diarrhoea or constipation, mouth sores or ulcers, higher risk of infection, elevated risk of bruises, hair loss, muscle spasms, dry or sleepy eyes, skin sensitivity to sunlight, and loss of appetite are among the adverse effects of chemotherapy.

Evidence suggests that these novel cancer treatments are improving patient outcomes, such as better tolerance, lower treatment burden, and improved survival for several patients. Immunotherapy does have the power to transform the cancer disease path from terminal to one of survival, as well as improve quality of life due to the varying spectrum (lower toxicity) of adverse effects.

Thus, the introduction of alternative treatments and drugs can hamper the demand for chemotherapy medications.


Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Country-wise Insights

Why is the U.S. a Huge Market for Chemotherapy Drug Manufacturers?

“Value-Based Payment Models for Cancer Treatment”

The U.S. accounted for around the largest share of the North American market in 2021, contributing nearly US$ 50.9 Bn in terms of revenue, and a similar trend is expected over the forecast period.

Around 5% of U.S. healthcare spending-and rising-goes toward treating the country's sizable and expanding number of cancer patients. Increasing insurance coverage and aging are two population-related factors. Additionally, cancer patients live longer if diagnosed earlier. Treatment expenses are rising because of procedurally advanced operations, radiation treatments, and anticancer drugs, including targeted medicines and enhanced immunotherapies.

  • A value-based payment model such as Oncology Care Model by the CMS Innovation Center, to assist in managing and coordinating care, practices will receive a US$ 160 per-beneficiary-per-month (PBPM), Monthly Enhanced Oncology Services (MEOS) reimbursement. Episodes commence with the start of chemotherapy and include costs for six months of chemotherapy and additional treatments.

Thus, the demand for chemotherapy drugs has increased in the U.S. in consideration of these reimbursement policies on the treatment of cancer and the rise of the adult population, thus promoting the value of the overall market.

What is the Scenario for Chemotherapy Drugs in the U.K.?

“Partnerships between Manufacturers and Government Associations”

The U.K. held 36.6% share of the Europe market in 2021.

Companies and government facilities are working together. Pharmaceutical firms are partnered with NHS England and the National Institute for Health and Care Excellence (NICE) to address the ambiguity around the efficacy of novel cancer treatments, which includes chemotherapeutic drugs.

Typically, during a managed access period when patients can obtain the medication, extra data is collected. The additional information aids NICE in determining whether to consistently support a new treatment or medication. This saves time, controls expenditure, allows funding opened for new patients, and gives manufacturers a scope for improvement.

Such strong support from the government is enabling the U.K. to prosper, becoming a lucrative market for chemotherapy drug manufacturers.

How is Australia Emerging as a Prominent Market for Chemotherapy Drugs?

“Improvement in Treatment Outcomes”

Australia held the largest market share of 90.8% of the Oceania market in 2021.

  • Australia has a significant cancer problem. According to projections by Cancer Australia, 162,163 new cases of cancer would be discovered in Australia by the end of 2022. By the age of 85, 43% of people-or around 2 in 5-will have received a cancer diagnosis.

The Australian government has gradually increased its investment in cancer treatment through increased access to healthcare and donations to research. Hence, government investments and rising cancer prevalence will drive the Australian market over the coming years.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Category-wise Insights

Which Drug Class is Largely the Focus in the Global Market?

“Efficiency and Effectiveness of Alkylating Agents”

The alkylating agents segment dominated the market generating a revenue of US$ 47.5 Bn in 2021.

Alkylating drugs were widely used from the start and are thus the best-studied chemotherapeutic drug. Although they can be used to treat a variety of cancers, they are most effective against slow-growing malignancies. The efficient mechanism of the drug and effective results have made it the most commonly used and in-demand drug class in the chemotherapy drugs market, thus accelerating market growth.

Which Indication Displays Greater Adoption of Chemotherapy Drugs?

“High Use of Chemotherapy Drugs for Cancer”

Cancer held the largest market share under the indication segment globally in 2021. The segment contributed revenue of US$ 110.5 Bn in 2021.

The immune system disorders segment is expected to be the most lucrative growing at a CAGR of 9.7%. The incidence of cancer is rising globally, and there are several clear causes for this, including smoking, drinking, pollution, and others. Cancer can be entirely cured if detected early and treated effectively, but a sizable portion of the population lacks access to healthcare. Therefore, among all indications, cancer held the largest market share.

Competitive Landscape

Leading manufacturers are incorporating technologically improved products to bolster their product ranges globally. Several significant competitors in the chemotherapy drugs sector have carried out similar consolidation actions such as mergers and acquisitions. The expansion of company partnerships to improve their chemotherapy drugs is another important strategy observed in the sector.

For instance:

  • Sierra Oncology, a late-stage biopharmaceutical business, was acquired by GSK for $1.9 billion, per a deal reached in April 2022.
  • According to Cipla’s September 2022 announcement, the US health regulator has approved Lenalidomide capsule, a medication used to treat several types of cancer.
  • On August 20, 2022, the Indian Drugs Controller General granted AstraZeneca India authorization to market Lynparza, a medication used to treat breast cancer.

Similarly, recent developments related to companies manufacturing chemotherapy drugs have been tracked by the team at Persistence Market Research, which are available in the full report.

Chemotherapy Drugs Industry Report Scope



Forecast Period


Historical Data Available for


Market Analysis

USD Billion for Value

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Mexico
  • Argentina
  • U.K.
  • Germany
  • Italy
  • Russia
  • Spain
  • France
  • India
  • Thailand
  • Indonesia
  • Malaysia
  • Japan
  • China
  • South Korea
  • India
  • Indonesia
  • Malaysia
  • Thailand
  • Australia
  • New Zealand
  • Turkey
  • GCC Countries
  • Northern Africa
  • South Africa

Key Market Segments Covered

  • Drug Class
  • Indication
  • Route of Administration
  • Dosage Form
  • Distribution channel
  • Region

Key Companies Profiled

  • F. Hoffmann-La Roche Ltd
  • Celgene Corp
  • Novartis AG
  • Bristol-Myers Squibb Co
  • Johnson & Johnson
  • Sanofi
  • Pfizer Inc.
  • Eli Lilly & Company
  • ImClone Systems Inc.
  • GlaxoSmithKline
  • AstraZeneca
  • Schering-Plough
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Teva Pharmaceuticals Industries
  • E. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Chemo Espana SL
  • Amgen Inc
  • Bayer AG
  • Takeda Pharmaceutical Company Limited

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Segments of Chemotherapy Drugs Industry Research

By Drug Class:

  • Alkylating Agents
  • Antimetabolites
  • Anti-tumour Antibiotics
  • Topoisomerase Inhibitors
  • Mitotic Inhibitors
  • Plant Alkaloids
  • Corticosteroids
  • Miscellaneous Antineoplastic

By Indication:

  • Cancer
  • Bone Marrow Diseases
  • Immune System Disorders
  • Others

By Route of Administration:

  • Oral
  • Parenteral
  • Others

By Dosage Form:

  • Capsules/Tablets
  • Injections
  • Others

By Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Ambulatory Surgical Centers

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • F. Hoffmann-La Roche Ltd
  • Celgene Corp
  • Novartis AG
  • Bristol-Myers Squibb Co
  • Johnson & Johnson
  • Sanofi
  • Pfizer Inc.
  • Eli Lilly & Company
  • ImClone Systems Inc.
  • GlaxoSmithKline
  • AstraZeneca
  • Schering-Plough
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Teva Pharmaceuticals Industries
  • E. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Chemo Espana SL
  • Amgen Inc
  • Bayer AG
  • Takeda Pharmaceutical Company Limited

- Frequently Asked Questions -

The global chemotherapy drugs market stands at US$ 157.7 Bn in 2022.

Sales of chemotherapy drugs are set to witness high growth at a CAGR of 7.7% and reach US$ 331.3 Bn by 2032.

Demand for chemotherapy drugs increased at 6.4% CAGR from 2012 to 2021.

The U.S., Australia, Canada, Germany, and the U.K. account for the most demand for chemotherapy drugs, currently holding 59.6% market share.

The U.S. accounts for the largest share of the North American market, contributing revenue of around US$ 50.9 Bn.

Sanofi, Pfizer Inc., and Eli Lilly & Company are the top three manufacturers of chemotherapy drugs.

China held a share of 42.7% in the East Asia market in 2021, while Japan is estimated to grow at a CAGR of 7.4%.

Demand for chemotherapy medications in Europe accounted for 30.3% share of the global market in 2021.

Increased focus on enhancing drug efficacy, novel drug launches, and favorable regulatory scenarios are some of the key trends in this market.

The North American market is set to expand at a CAGR of 8.1% through 2032.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate